Summary of Significant Accounting Policies - Other (Details) $ in Thousands |
6 Months Ended | |
|---|---|---|
|
Jun. 30, 2024
USD ($)
customer
|
Dec. 31, 2023
USD ($)
|
|
| Product Revenue, net | ||
| Number of customers | customer | 3 | |
| Trade Receivables, net | ||
| Accounts receivable, net | $ 3,435 | $ 3,799 |
| Allowance for doubtful accounts. | $ 0 | 0 |
| Payment terms | 30 days | |
| ZTALMY | ||
| Trade Receivables, net | ||
| Accounts receivable, net | $ 2,900 | $ 2,600 |
| Inventory | ||
| Cost of product and materials included in research and development expenses prior to FDA approval | $ 2,000 | |
| ZTALMY | Revenue Benchmark | Customer Concentration Risk | ||
| Product Revenue, net | ||
| Concentration risk, as a percent | 99.00% | |
| Number of customers | customer | 1 |